|
1
|
Ring A and Dowsett M: Mechanisms of
tamoxifen resistance. Endocr Relat Cancer. 11:643–658. 2004.
View Article : Google Scholar
|
|
2
|
Greenspan EM: Tamoxifen in early breast
cancer. Lancet. 1:6551983. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rose C, Thorpe SM, Andersen KW, Pedersen
BV, Mouridsen HT, Blichert-Toft M and Rasmussen BB: Beneficial
effect of adjuvant tamoxifen therapy in primary breast cancer
patients with high oestrogen receptor values. Lancet. 1:16–19.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shiau AK, Barstad D, Loria PM, Cheng L,
Kushner PJ, Agard DA and Greene GL: The structural basis of
estrogen receptor/coactivator recognition and the antagonism of
this interaction by tamoxifen. Cell. 95:927–937. 1998. View Article : Google Scholar
|
|
5
|
Stewart HJ and Prescott R: Adjuvant
tamoxifen therapy and receptor levels. Lancet. 1:5731985.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paige AJ, Taylor KJ, Taylor C, Hillier SG,
Farrington S, Scott D, Porteous DJ, Smyth JF, Gabra H and Watson
JE: WWOX: a candidate tumor suppressor gene involved in multiple
tumor types. Proc Natl Acad Sci USA. 98:11417–11422. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aqeilan RI, Trapasso F, Hussain S,
Costinean S, Marshall D, Pekarsky Y, Hagan JP, Zanesi N, Kaou M,
Stein GS, et al: Targeted deletion of Wwox reveals a tumor
suppressor function. Proc Natl Acad Sci USA. 104:3949–3954. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bednarek AK, Laflin KJ, Daniel RL, Liao Q,
Hawkins KA and Aldaz CM: WWOX, a novel WW domain-containing protein
mapping to human chromosome 16q23.3-24.1, a region frequently
affected in breast cancer. Cancer Res. 60:2140–2145.
2000.PubMed/NCBI
|
|
9
|
Nunez MI, Ludes-Meyers J, Abba MC, Kil H,
Abbey NW, Page RE, Sahin A, Klein-Szanto AJ and Aldaz CM: Frequent
loss of WWOX expression in breast cancer: correlation with estrogen
receptor status. Breast Cancer Res Treat. 89:99–105. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Płuciennik E, Kusińska R, Potemski P,
Kubiak R, Kordek R and Bednarek AK: WWOX - the FRA16D cancer gene:
expression correlation with breast cancer progression and
prognosis. Eur J Surg Oncol. 32:153–157. 2006.PubMed/NCBI
|
|
11
|
Driouch K, Prydz H, Monese R, Johansen H,
Lidereau R and Frengen E: Alternative transcripts of the candidate
tumor suppressor gene, WWOX, are expressed at high levels in human
breast tumors. Oncogene. 21:1832–1840. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guler G, Uner A, Guler N, Han SY,
Iliopoulos D, Hauck WW, McCue P and Huebner K: The fragile genes
FHIT and WWOX are inactivated coordinately in invasive breast
carcinoma. Cancer. 100:1605–1614. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nunez MI, Ludes-Meyers J and Aldaz CM:
WWOX protein expression in normal human tissues. J Mol Histol.
37:115–125. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bednarek AK, Keck-Waggoner CL, Daniel RL,
Laflin KJ, Bergsagel PL, Kiguchi K, Brenner AJ and Aldaz CM: WWOX,
the FRA16D gene, behaves as a suppressor of tumor growth. Cancer
Res. 61:8068–8073. 2001.PubMed/NCBI
|
|
15
|
Aqeilan RI, Kuroki T, Pekarsky Y, Albagha
O, Trapasso F, Baffa R, Huebner K, Edmonds P and Croce CM: Loss of
WWOX expression in gastric carcinoma. Clin Cancer Res.
10:3053–3058. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baykara O, Demirkaya A, Kaynak K, Tanju S,
Toker A and Buyru N: WWOX gene may contribute to progression of
non-small-cell lung cancer (NSCLC). Tumour Biol. 31:315–320. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bloomston M, Kneile J, Butterfield M,
Dillhoff M, Muscarella P, Ellison EC, Melvin WS, Croce CM,
Pichiorri F, Huebner, et al: Coordinate loss of fragile gene
expression in pancreatobiliary cancers: correlations among markers
and clinical features. Ann Surg Oncol. 16:2331–2338. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fabbri M, Iliopoulos D, Trapasso F,
Aqeilan RI, Cimmino A, Zanesi N, Yendamuri S, Han SY, Amadori D,
Huebner K, et al: WWOX gene restoration prevents lung cancer growth
in vitro and in vivo. Proc Natl Acad Sci USA. 102:15611–15616.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Finnis M, Dayan S, Hobson L,
Chenevix-Trench G, Friend K, Ried K, Venter D, Woollatt E, Baker E
and Richards RI: Common chromosomal fragile site FRA16D mutation in
cancer cells. Hum Mol Genet. 14:1341–1349. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iliopoulos D, Guler G, Han SY, Johnston D,
Druck T, McCorkell KA, Palazzo J, McCue PA, Baffa R and Huebner K:
Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in
lung, breast and bladder cancer. Oncogene. 24:1625–1633. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Iliopoulos D, Fabbri M, Druck T, Qin HR,
Han SY and Huebner K: Inhibition of breast cancer cell growth in
vitro and in vivo: effect of restoration of Wwox expression. Clin
Cancer Res. 13:268–274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuroki T, Yendamuri S, Trapasso F,
Matsuyama A, Aqeilan RI, Alder H, Rattan S, Cesari R, Nolli ML,
Williams NN, et al: The tumor suppressor gene WWOX at FRA16D is
involved in pancreatic carcinogenesis. Clin Cancer Res.
10:2459–2465. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
O’Keefe LV, Liu Y, Perkins A, Dayan S,
Saint R and Richards RI: FRA16D common chromosomal fragile site
oxido-reductase (FOR/WWOX) protects against the effects of ionizing
radiation in Drosophila. Oncogene. 24:6590–6596.
2005.PubMed/NCBI
|
|
24
|
Park SW, Ludes-Meyers J, Zimonjic DB,
Durkin ME, Popescu NC and Aldaz CM: Frequent downregulation and
loss of WWOX gene expression in human hepatocellular carcinoma. Br
J Cancer. 91:753–759. 2004.PubMed/NCBI
|
|
25
|
Qin HR, Iliopoulos D, Semba S, Fabbri M,
Druck T, Volinia S, Croce CM, Morrison CD, Klein RD and Huebner K:
A role for the WWOX gene in prostate cancer. Cancer Res.
66:6477–6481. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guler G, Uner A, Guler N, Han SY,
Iliopoulos D, McCue P and Huebner K: Concordant loss of fragile
gene expression early in breast cancer development. Pathol Int.
55:471–478. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang NS, Schultz L, Hsu LJ, Lewis J, Su M
and Sze CI: 17beta-Estradiol upregulates and activates WOX1/WWOXv1
and WOX2/WWOXv2 in vitro: potential role in cancerous progression
of breast and prostate to a premetastatic state in vivo. Oncogene.
24:714–723. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guler G, Himmetoglu C, Jimenez RE, Geyer
SM, Wang WP, Costinean S, Pilarski RT, Morrison C, Suren D, Liu J,
et al: Aberrant expression of DNA damage response proteins is
associated with breast cancer subtype and clinical features. Breast
Cancer Res Treat. 129:421–432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aqeilan RI, Pekarsky Y, Herrero JJ,
Palamarchuk A, Letofsky J, Druck T, Trapasso F, Han SY, Melino G,
Huebner K, et al: Functional association between Wwox tumor
suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci USA.
101:4401–4406. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang NS, Doherty J, Ensign A, Schultz L,
Hsu LJ and Hong Q: WOX1 is essential for tumor necrosis factor-, UV
light-, staurosporine-, and p53-mediated cell death, and its
tyrosine 33-phosphorylated form binds and stabilizes serine
46-phosphorylated p53. J Biol Chem. 280:43100–43108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guler G, Iliopoulos D, Guler N, Himmetoglu
C, Hayran M and Huebner K: Wwox and Ap2gamma expression levels
predict tamoxifen response. Clin Cancer Res. 13:6115–6121. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guler G, Huebner K, Himmetoglu C, Jimenez
RE, Costinean S, Volinia S, Pilarski RT, Hayran M and Shapiro CL:
Fragile histidine triad protein, WW domain-containing
oxidoreductase protein Wwox, and activator protein 2gamma
expression levels correlate with basal phenotype in breast cancer.
Cancer. 115:899–908. 2009. View Article : Google Scholar
|
|
33
|
Aqeilan RI, Donati V, Palamarchuk A,
Trapasso F, Kaou M, Pekarsky Y, Sudol M and Croce CM: WW
domain-containing proteins, WWOX and YAP, compete for interaction
with ErbB-4 and modulate its transcriptional function. Cancer Res.
65:6764–6772. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aqeilan RI, Donati V, Gaudio E, Nicoloso
MS, Sundvall M, Korhonen A, Lundin J, Isola J, Sudol M, Joensuu H,
et al: Association of Wwox with ErbB4 in breast cancer. Cancer Res.
67:9330–9336. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Abdeen SK, Salah Z, Maly B, Smith Y,
Tufail R, Abu-Odeh M, Zanesi N, Croce CM, Nawaz Z and Aqeilan RI:
Wwox inactivation enhances mammary tumorigenesis. Oncogene.
30:3900–3906. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rutqvist LE, Johansson H and Group SBCS:
Long-term follow-up of the randomized Stockholm trial on adjuvant
tamoxifen among postmenopausal patients with early stage breast
cancer. Acta Oncol. 46:133–145. 2007. View Article : Google Scholar
|
|
37
|
Wang X, Chao L, Ma G, Chen L, Zang Y and
Sun J: The prognostic significance of WWOX expression in patients
with breast cancer and its association with the basal-like
phenotype. J Cancer Res Clin Oncol. 137:271–278. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fox EM, Andrade J and Shupnik MA: Novel
actions of estrogen to promote proliferation: integration of
cytoplasmic and nuclear pathways. Steroids. 74:622–627. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang Z, Barnes CJ and Kumar R: Human
epidermal growth factor receptor 2 status modulates subcellular
localization of and interaction with estrogen receptor alpha in
breast cancer cells. Clin Cancer Res. 10:3621–3628. 2004.
View Article : Google Scholar
|
|
40
|
Watanabe A, Hippo Y, Taniguchi H, Iwanari
H, Yashiro M, Hirakawa K, Kodama T and Aburatani H: An opposing
view on WWOX protein function as a tumor suppressor. Cancer Res.
63:8629–8633. 2003.PubMed/NCBI
|
|
41
|
Qin HR, Iliopoulos D, Nakamura T,
Costinean S, Volinia S, Druck T, Sun J, Okumura H and Huebner K:
Wwox suppresses prostate cancer cell growth through modulation of
ErbB2-mediated androgen receptor signaling. Mol Cancer Res.
5:957–965. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Belsches-Jablonski AP, Biscardi JS, Peavy
DR, Tice DA, Romney DA and Parsons SJ: Src family kinases and HER2
interactions in human breast cancer cell growth and survival.
Oncogene. 20:1465–1475. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Morgan L, Gee J, Pumford S, Farrow L,
Finlay P, Robertson J, Ellis I, Kawakatsu H, Nicholson R and Hiscox
S: Elevated Src kinase activity attenuates Tamoxifen response in
vitro and is associated with poor prognosis clinically. Cancer Biol
Ther. 8:1550–1558. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pellikainen J, Naukkarinen A, Ropponen K,
Rummukainen J, Kataja V, Kellokoski J, Eskelinen M and Kosma VM:
Expression of HER2 and its association with AP-2 in breast cancer.
Eur J Cancer. 40:1485–1495. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Junttila TT, Sundvall M, Lundin M, Lundin
J, Tanner M, Härkönen P, Joensuu H, Isola J and Elenius K:
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of
breast cancer cells. Cancer Res. 65:1384–1393. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Naresh A, Thor AD, Edgerton SM, Torkko KC,
Kumar R and Jones FE: The HER4/4ICD estrogen receptor coactivator
and BH3-only protein is an effector of tamoxifen-induced apoptosis.
Cancer Res. 68:6387–6395. 2008. View Article : Google Scholar : PubMed/NCBI
|
